The MarketWatch News Department was not involved in the creation of this content. -- Expansion into larger, more advanced manufacturing space and enables new production capabilities, additional ...

Expansion into larger, more advanced manufacturing space and enables new production capabilities, additional product lines and creation of new jobs. Parent company Randoncorp committed to ...

AXN Automotive Systems has completed an expansion of its manufacturing facility in Louisville, Kentucky, as the parts supplier grows its U.S. footprint and North American customer base. The plant ...

Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M. In a ...

For Instil Bio, the decision to halt development of AXN-2510 represents a significant shift in its clinical pipeline strategy. The company’s announcement also noted various risk factors that could ...

FAYETTEVILLE, GA — An investigation is underway after a dog was found zipped up inside a suitcase that was thrown in a dumpster near the square in Fayetteville. Fayette County officials say they are ...

As Spain continues to cement its position among the world’s most dynamic exporters of scripted TV, Atresmedia Sales has unveiled a key deal with AXN Japan on detective drama “Una vida menos en ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Colleen Hagerty Colleen Hagerty is a writer focused on emergency preparedness.

The study will assess safety, efficacy, pharmacokinetics and pharmacodynamics. "Evaluating AXN-2510 in a global population will be a critical milestone in the clinical development of AXN-2510," said ...

Instil Bio (TIL) and its partner ImmuneOnco have been doing well to advance their potential best-in-class PD-1/VEGF bispecific antibody AXN-2510 for the treatment of patients with solid tumors. The ...